Objective: To explore the application value of contrast-enhanced ultrasound perfusion parameters in the diagnosis of endometrial carcinoma and analyze their relationship with clinicopathological characteristics. Methods: A total of 104 patients with endometrial carcinoma and 90 patients with benign endometrial diseases (68 cases with endometrial polyps and 22 cases with submucosal fibroids) in the hospital were enrolled between March 2019 and February 2022. All underwent preoperative contrast-enhanced ultrasonography. Taking pathological results as the golden standard, application value of ultrasonography parameters [rise time (RT), time to peak (TTP), peak intensity (PI), mean transit time (MTT)] in the diagnosis of endometrial carcinoma and evaluation of clinicopathological characteristics was analyzed. Results: RT, TTP and MTT in endometrial carcinoma were shorter than those in benign endometrial lesions, and PI was greater than that in benign endometrial lesions (P<0.05). The area under ROC curve (AUC) of RT combined with PI, TTP and MTT in the differential diagnosis of endometrial carcinoma and benign endometrial lesions was 0.903, greater than that of single index (0.742, 0.634, 0.804, 0.657, P<0.05). RT, TTP and MTT in patients with FIGO staging at stages III-IV were shorter than those at stages I-II, and PI was higher than that at stages I-II (P<0.05). AUC of RT combined with PI, TTP and MTT in the differential diagnosis of stages I-II and stages III-IV was 0.842, greater than that of single index (0.727, 0.641, 0.753, 0.627, P<0.05). RT, TTP and MTT in patients with lymph node metastasis were shorter than those without metastasis, and PI was higher than that without metastasis (P<0.05). AUC of RT combined with PI, TTP and MTT for evaluating lymph node metastasis was 0.832, greater than that of single index (0.675, 0.659, 0.726, 0.704, P<0.05). Conclusion: Quantitative examination of blood perfusion by contrast-enhanced ultrasound can reflect the blood flow in endometrial carcinoma, which has guidance significance for clinical diagnosis, pathological staging and evaluation of lymph node metastasis.